148 related articles for article (PubMed ID: 2887309)
1. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma.
Verschoor L; Uitterlinden P; Lamberts SW; Del Pozo E
Clin Endocrinol (Oxf); 1986 Nov; 25(5):555-60. PubMed ID: 2887309
[TBL] [Abstract][Full Text] [Related]
2. [Preoperative treatment of hypoglycemia caused by an insulinoma with the somatostatin analog SMS 201-995].
Sánchez García Cervigón P; Fernández Navarro JI; Salmerón de Diego J; Caballero Asensi A; Cornelio Hernández F; Jara Albarrán A
Med Clin (Barc); 1987 Oct; 89(12):511-3. PubMed ID: 2890800
[No Abstract] [Full Text] [Related]
3. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report.
Alberts AS; Falkson G
S Afr Med J; 1988 Jul; 74(2):75-6. PubMed ID: 2899913
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
Glaser B; Rösler A; Halperin Y
Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
[TBL] [Abstract][Full Text] [Related]
5. Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas.
Utas C; Kelestimur F; Boyaci A; Saglam A
Postgrad Med J; 1993 Dec; 69(818):920-1. PubMed ID: 8121865
[TBL] [Abstract][Full Text] [Related]
6. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.
Reubi JC
Acta Endocrinol (Copenh); 1985 May; 109(1):108-14. PubMed ID: 2860768
[TBL] [Abstract][Full Text] [Related]
7. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).
Stehouwer CD; Lems WF; Fischer HR; Hackeng WH; Naafs MA
Acta Endocrinol (Copenh); 1989 Jul; 121(1):34-40. PubMed ID: 2545062
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995.
Kung AW; Ma JT; Wang C; Fu KH; Lam KS; Yeung RT; Boey J
Clin Endocrinol (Oxf); 1987 Oct; 27(4):469-73. PubMed ID: 2893673
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
Simpson KW; Stepien RL; Elwood CM; Boswood A; Vaillant CR
J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057
[TBL] [Abstract][Full Text] [Related]
10. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.
Maton PN; O'Dorisio TM; Howe BA; McArthur KE; Howard JM; Cherner JA; Malarkey TB; Collen MJ; Gardner JD; Jensen RT
N Engl J Med; 1985 Jan; 312(1):17-21. PubMed ID: 2856888
[No Abstract] [Full Text] [Related]
11. Long-term use of somatostatin analogue SMS 201-995 in the treatment of hypoglycaemia due to nesidioblastosis.
Wilson DC; Carson DJ; Quinn RJ
Acta Paediatr Scand; 1988 May; 77(3):467-70. PubMed ID: 2898862
[TBL] [Abstract][Full Text] [Related]
12. [Hypoglycemia caused by insulinoma in diabetes mellitus].
Heik SC; Klöppel G; Krone W; Iben G; Priebe K; Kühnau J
Dtsch Med Wochenschr; 1988 Nov; 113(44):1714-7. PubMed ID: 2846254
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
[TBL] [Abstract][Full Text] [Related]
14. [Metabolic control of insulinoma with a prolonged-action somatostatin agonist].
Kaloustian E
Presse Med; 1986 Oct; 15(37):1881-2. PubMed ID: 2878428
[No Abstract] [Full Text] [Related]
15. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
Spinas GA; Bock A; Keller U
Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
[TBL] [Abstract][Full Text] [Related]
16. Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.
Krentz AJ; Pace J; Somerville W; Clark PM; Nattrass M
Postgrad Med J; 1993 Sep; 69(815):735-8. PubMed ID: 8255845
[TBL] [Abstract][Full Text] [Related]
17. Studies on insulin secretion by monolayer cultures of normal and tumorous human pancreatic cells. Effects of glucose, somatostatin and SMS 201-995.
Oosterom R; Verleun T; Uitterlinden P; Bruining HA; Bruining GJ; Verschoor L; Lamberts SW
J Endocrinol Invest; 1987 Dec; 10(6):547-52. PubMed ID: 2894388
[TBL] [Abstract][Full Text] [Related]
18. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma.
Timmer R; Koningsberger JC; Erkelens DW; Thijssen JH; Lips CJ; Koppeschaar HP
Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
20. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
Osei K; O'Dorisio TM
Ann Intern Med; 1985 Aug; 103(2):223-5. PubMed ID: 2861769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
